Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1989 Nov;68(3):434–435.

Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.

P Walliser 1, C R Benzie 1, J E Kay 1
PMCID: PMC1385461  PMID: 2480331

Abstract

The novel immunosuppressive drug FK-506 inhibits both cell-mediated and humoral immunity in vivo and suppresses T-lymphocyte activation at nanamolar concentrations in vitro. We report here that FK-506 also inhibits the in vitro proliferation of murine B lymphocytes induced by goat antimouse IgM (GaMIgM), although it does not affect the induction of proliferation by bacterial lipopolysaccharide (LPS). The action of FK-506 on B-lymphocyte proliferation thus resembles that of cyclosporin A, further strengthening the correlation between the action of the two immunosuppressive drugs previously reported for T-lymphocyte activation.

Full text

PDF
434

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dongworth D. W., Klaus G. G. Effects of cyclosporin A on the immune system of the mouse. I. Evidence for a direct selective effect of cyclosporin A on B cells responding to anti-immunoglobulin antibodies. Eur J Immunol. 1982 Dec;12(12):1018–1022. doi: 10.1002/eji.1830121207. [DOI] [PubMed] [Google Scholar]
  2. Kay J. E., Benzie C. R., Goodier M. R., Wick C. J., Doe S. E. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. Immunology. 1989 Aug;67(4):473–477. [PMC free article] [PubMed] [Google Scholar]
  3. Kay J. E. The cyclosporin-A-sensitive event in lymphocyte activation. Ann Inst Pasteur Immunol. 1987 Jul-Aug;138(4):622–625. doi: 10.1016/s0769-2625(87)80134-4. [DOI] [PubMed] [Google Scholar]
  4. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987 Sep;40(9):1249–1255. doi: 10.7164/antibiotics.40.1249. [DOI] [PubMed] [Google Scholar]
  5. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 Sep;40(9):1256–1265. doi: 10.7164/antibiotics.40.1256. [DOI] [PubMed] [Google Scholar]
  6. Klaus G. G. Cyclosporin as a probe for different modes of lymphocyte activation. Ann Inst Pasteur Immunol. 1987 Jul-Aug;138(4):626–628. doi: 10.1016/s0769-2625(87)80135-6. [DOI] [PubMed] [Google Scholar]
  7. Sawada S., Suzuki G., Kawase Y., Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987 Sep 15;139(6):1797–1803. [PubMed] [Google Scholar]
  8. Walls E. V., Kay J. E. Inhibition of proliferation of a murine myeloma cell line and mitogen-stimulated B lymphocytes by the antibiotic amphotericin B (Fungizone). Immunology. 1982 Sep;47(1):115–121. [PMC free article] [PubMed] [Google Scholar]
  9. Warty V., Diven W., Cadoff E., Todo S., Starzl T., Sanghvi A. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. Transplantation. 1988 Sep;46(3):453–455. doi: 10.1097/00007890-198809000-00025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Woo J., Stephen M., Thomson A. W. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology. 1988 Sep;65(1):153–155. [PMC free article] [PubMed] [Google Scholar]
  11. Yoshimura N., Matsui S., Hamashima T., Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation. 1989 Feb;47(2):351–356. doi: 10.1097/00007890-198902000-00034. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES